The Global Alliance for TB Drug Development
) is a non-profit organization dedicated to the discovery and development of new, faster-acting and affordable tuberculosis
The TB Alliance expects to register a new anti-TB regimen that could cut the duration of tuberculosis treatment
one-third by 2013. In the long-term, the TB Alliance’s goal is to develop a drug regimen that will reduce TB treatment to 10 doses from 130; be effective against drug resistant strains of TB; work with the antiretroviral drugs
used to treat HIV
; and improve the treatment of latent TB infection.
infects one third of the world’s population, kills two million people each year, and costs the global economy $16 billion annually. However, research and development for new TB drugs came to a virtual standstill after the 1960s. Today, a four drug combination therapy exists, but it takes six months or more to be effective. This requires a degree of monitoring (See Direct Observational Therapy, Shortcourse
) beyond the capacity of the health infrastructure in many countries; adequate TB treatment is available to less than half of the most infectious cases. This can inhibit control of the disease and fuel the rise of drug resistance
. TB is also the number one killer of AIDS
patients, but it is generally agreed that current TB treatments do not work well with the antiretroviral drugs
used to treat HIV.
The TB drug market lacks sufficient financial incentives to... Read More